Affordable Access

The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b.

Authors
  • Rice, G P
  • Paszner, B
  • Oger, J
  • Lesaux, J
  • Paty, D
  • Ebers, G
Type
Published Article
Journal
Neurology
Publisher
Ovid Technologies (Wolters Kluwer) - American Academy of Neurology
Publication Date
Apr 11, 1999
Volume
52
Issue
6
Pages
1277–1279
Identifiers
PMID: 10214759
Source
Medline
License
Unknown

Abstract

The fate of the neutralizing antibody (NAB) in MS patients treated with interferons remains unclear. We conducted a follow-up survey of NAB titers in 59 long-term treated patients from the London and Vancouver cohorts of the pivotal trial of interferon alpha-1b. NAB were measured with the myxovirus protein A assay and an ELISA, at a mean follow-up that exceeded 8 years. NAB disappeared in the majority of patients.

Report this publication

Statistics

Seen <100 times